For research use only. Not for use in humans.

Mirvetuximab (Anti-FOLR1)

Synonyms: FRA, FR-alpha

Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD

Mirvetuximab (Anti-FOLR1)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD

Product Details

CAS No. 1453084-36-0
Molecular Weight 145.2 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06890338 RECRUITING Drug: Carboplatin|Drug: Mirvetuximab Soravtansine|Drug: Beva Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Neoadjuvant AbbVie 2025-11-21 PHASE2
NCT05887609 RECRUITING Drug: Mirvetuximab Soravtansine-gynx|Drug: Olaparib Ovary Cancer; Peritoneal Cancer; Fallopian Tube Cancer University of Colorado, Denver 2023-10-03 PHASE2
NCT07059845 RECRUITING Drug: Mirvetuximab Soravtansine|Drug: Bevacizumab|Drug: Carb Ovarian Cancer AbbVie 2025-11-13 PHASE2
NCT07218809 RECRUITING Drug: AZD5335|Drug: Mirvetuximab Soravtansine (MIRV)|Drug: P Epithelial Ovarian Cancer AstraZeneca 2025-12-29 PHASE3
NCT07213804 RECRUITING Drug: Sofetabart Mipitecan|Drug: Paclitaxel|Drug: Topotecan| Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis Eli Lilly and Company 2025-10-22 PHASE3
NCT07790939 NOT_YET_RECRUITING Epithelial Ovarian Cancer; Ovarian Cancer Peking University Cancer Hospital & Institute 2026-09-01 EARLY_PHASE1

(data from https://clinicaltrials.gov, updated on 2026-09-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.